IRB Study Number 23-132
Status Recruiting
Location Cleveland Clinic Main Campus
Institute Endocrinology and Metabolism Institute
Description
This is a prospective specimen collection cohort study aimed to increase the detection of primary aldosteronism (PA) in patients with hypertension.
Inclusion Criteria
- Consent to participate in the study
- Participants limited to subjects in the CCF
- Age between and inclusive of 18 and 75 years of age
- No gender exclusion
- Patients diagnosed with Essential Hypertension by ICD-10 code on at least two occasions in the previous six months, even if not on medications for hypertension
- Patients with essential hypertension on two antihypertensive (beta blocker, ACE or ARB or Calcium channel blocker or diuretic and/or those on a combination therapy consisting of ACE or ARB plus a diuretic).
Exclusion Criteria
- Those on a mineralocorticoid antagonist therapy (spironolactone, eplerenone)
- Those with a documented diagnosis of primary aldosteronism or primary hyperaldosteronism
- Those with a diagnosis of secondary hyperaldosteronism
- Those with a diagnosis of heart failure, renal artery stenosis, cirrhosis, ascites, and or pulmonale.
- Pregnancy status (verbal)
- Those on oral contraceptives
